Supplementary Fig. 1 Design of the animal interventions.

(A) Kinetics of plasma glucuronidase induction in LPS-induced inflammation

(B) Uro-A plasma pharmacokinetics

(C) Effect of LPS-induced inflammation on Uro-A metabolites deconjugation

Analysis:
- Plasma
- Urine
- Stomach
- Small intestine
- Colon-faeces
- Liver
- Spleen
- Kidney
- Bladder
- Lung
Supplementary Fig. 2 Kinetics of plasma β-glucuronidase activity after LPS i.p. administration.

Results are shown as mean ± SD. Differences in mean parameter values among treatment groups were determined by one-way RM ANOVA. In cases where overall statistical significance was determined, the data were further analyzed by all pair-wise multiple comparison (Holm-Sidak method). Different letters designate statistical significance (P<0.05).
Supplementary Figure 3. Plasma pharmacokinetics of Uro-A sulphate after oral Uro-A administration.

Mean values ± SD are shown.  ■ Control; ▲ LPS-treated rats.